Trial Profile
A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2022
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms TAISTR
- 29 Apr 2022 This trial has been discontinued in Spain according to European Clinical Trials Database record.
- 06 Feb 2022 This trial has been discontinued in Ireland (End Date: 06 Sep 2021), according to European Clinical Trials Database record.
- 25 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.